Kyntra Bio, Inc. (KYNB) AI Stock Analysis
KYNB AI stock analysis summary
AI ResearchKyntra Bio, Inc. is a biopharmaceutical company developing targeted therapeutics, including FG-3246 and Roxadustat. In FY2025, revenue contracted 78.3% to $6.4M, while the company reported net income of $183.5M. The business holds $91.3M in cash and short-term investments alongside -$30.1M in shareholders' equity as of June 30, 2026.
- Market cap
- $19.6M
- Revenue (TTM)
- $4.6M
- P/E
- — fwd 61.3x
- 1Y return
- -55.0% S&P 500 16.8%
- Avg. target
- $38.50 693.8% vs last close
Bull case
- Wall Street analysts hold a positive consensus with 4 Buy or Strong Buy ratings and a mean price target of $38.50, representing 693.8% upside from the last close.
- The company held $91.3M in cash and short-term investments as of June 30, 2026, exceeding its market cap of $19.6M.
- For the next fiscal year, analysts estimate revenue will grow 14.1% to $7.3M.
Bear case
- Revenue experienced a 5-year CAGR of -48.4% from FY2020 to FY2025, falling from $235.3M in FY2021 to $6.4M in FY2025.
- As of June 30, 2026, the company had negative shareholders' equity of -$30.1M alongside a trailing twelve-month EPS of -$7.64.
- The stock trades at a forward P/E of 61.3x and an EV-to-EBITDA of 44.1x, well above the US-listed Healthcare peer medians of 17.3x and 12.0x, respectively.
What Kyntra Bio does
Kyntra Bio, Inc., formerly known as FibroGen, Inc., is a biopharmaceutical company that discovers, develops, and commercializes therapeutics for serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46 for metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, an inhibitor of hypoxia-inducible factor prolyl hydroxylase activity that completed Phase III trials for anemia in chronic kidney disease and is in Phase III for anemia related to myelodysplastic syndromes. Kyntra Bio maintains collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB.
Growth and profitability
Kyntra Bio's revenue decreased significantly from $235.3M in FY2021 to $140.7M in FY2022, $46.8M in FY2023, and $29.6M in FY2024. In FY2025, revenue fell 78.3% to $6.4M, marking a 5-year revenue CAGR of -48.4% from FY2020 to FY2025. Despite an operating margin of -712.7% in FY2025, the company posted net income of $183.5M and a net margin of 2848.6%, up from net income of -$47.6M in FY2024. For the trailing twelve months ending June 30, 2026, revenue was $4.6M with an EPS of -$7.64, while quarterly revenue grew 36.5% year-over-year.
Balance sheet and cash flow
As of June 30, 2026, Kyntra Bio held $91.3M in cash and short-term investments, total assets of $101.1M, and a current ratio of 2.69. Shareholders' equity was -$30.1M, reflecting negative equity. In FY2025, operating cash flow and free cash flow were both -$4.8M, compared to free cash flow of -$138.3M in FY2024. Regarding cash deployment in FY2025, capital expenditures were $38,000, share buybacks totaled $69,000, and dividends paid were $3.9M.
Valuation and performance
At a closing price of $4.85 on October 16, 2026, Kyntra Bio had a market cap of $19.6M and an enterprise value of $79.7M. The stock trades at a forward P/E of 61.3x, above the 17.3x median of its US-listed Healthcare peers. Its price-to-sales multiple is 4.3x compared to the peer median of 4.1x, and its EV-to-EBITDA is 44.1x against the peer median of 12.0x. Over the past year, the stock fell 55.0%, while the S&P 500 gained 16.8%. Over five years, the stock dropped 98.2% compared to an 83.0% gain for the benchmark.
What analysts expect
Wall Street analysts maintain 3 Strong Buy, 1 Buy, and 1 Hold ratings on Kyntra Bio, with no Sell or Strong Sell ratings. The mean price target is $38.50, representing 693.8% upside from the last close of $4.85. For the fiscal year ending December 31, 2026, analysts forecast revenue of $6.4M and an EPS of -$12.41. For the next fiscal year, two analysts project revenue of $7.3M, reflecting 14.1% growth, and an EPS of -$14.23. The company beat EPS estimates in 2 of the last 4 quarters, and its next earnings date is November 9, 2026.
Key risks and what to watch
- Kyntra Bio reported an operating margin of -712.7% in FY2025 and is projected to report an EPS of -$12.41 for the fiscal year ending December 31, 2026.
- Negative shareholders' equity of -$30.1M as of June 30, 2026, presents ongoing balance sheet risk.
- The stock has lost significant market value, falling 55.0% over the past year and 98.2% over the past five years.
- Annual revenue remains volatile, dropping 78.3% in FY2025 to $6.4M.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this KYNB AI stock analysis
This page is an AI-written research summary of Kyntra Bio, Inc. (KYNB). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: KYNB income statement, KYNB balance sheet, KYNB key metrics, KYNB analyst forecast, KYNB chart. See the KYNB stock overview for the latest quote and news.
KYNB AI stock analysis FAQ
Why was the company renamed to Kyntra Bio, Inc.?
The company was formerly known as FibroGen, Inc. and changed its name to Kyntra Bio, Inc. in January 2026 while continuing clinical development of candidates such as FG-3246 and Roxadustat.
What is Kyntra Bio's cash and balance sheet status?
As of June 30, 2026, Kyntra Bio had $91.3M in cash and short-term investments and total assets of $101.1M. Shareholders' equity was -$30.1M, and the current ratio stood at 2.69.
What are analysts forecasting for KYNB's share price and revenue?
Analysts maintain a mean price target of $38.50, which is 693.8% above the October 16, 2026 close of $4.85. For the current fiscal year ending December 31, 2026, analysts expect revenue of $6.4M and an EPS of -$12.41.
How does Kyntra Bio's valuation compare to its peers?
Kyntra Bio trades at a forward P/E of 61.3x and an EV-to-EBITDA of 44.1x. These compare to peer medians of 17.3x and 12.0x, respectively, for US-listed Healthcare peers.